No Data
Orient: DNA methylation assists in the diagnosis and treatment of endometrial cancer. Pay attention to companies related to the Industry Chain.
DNA methylation has been confirmed to have auxiliary diagnostic value for early endometrial cancer. With its advantages of being earlier and less invasive, it has become one of the methods for early auxiliary diagnosis of various cancers.
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH): The actual controller has renewed the concerted action agreement.
Jiangsu Bioperfectus Technologies Co.,Ltd. (688399.SH) announced that it has received a notice from the actual controlling shareholders Mr. Fang Yongsheng, Mr. Liang Xilin, and Mr. Wang Guoqiang regarding the renewal of the "Joint Action Agreement". As the renewal of the "Joint Action Agreement" signed by all parties on December 5, 2023 had expired, in order to improve corporate governance, ensure the continuity and stability of the company's operation, and achieve effective and substantial control of the company, all parties renewed the "Joint Action Agreement".
Jiangsu Shuoshi Biotechnology Co., Ltd. Report for the Third Quarter of 2024
Some Shareholders Feeling Restless Over Jiangsu Bioperfectus Technologies Co., Ltd.'s (SHSE:688399) P/S Ratio
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH): has not yet launched business in the field of cell therapy
Jiangsu Bioperfectus Technologies Co., Ltd. (688399.SH) stated on the investor interaction platform that the company is currently focused on the research and development, production, and sales of in vitro diagnostic reagents, supporting testing instruments, and other in vitro diagnostic products. It focuses on disease prevention and control (CDC) and clinical maternal and child testing, and has not yet engaged in the field of cell therapy business.
Jiangsu Bioperfectus Technologies Co.,Ltd. (688399.SH): has repurchased 2.07% of the shares.
On September 2, Gleonhui announced that as of September 2, 2024, Jiangsu Bioperfectus Technologies Co.,Ltd. (688399.SH) has repurchased a total of 1.21066 million shares through centralized bidding trading, accounting for 2.07% of the total share capital. The highest purchase price is 79.70 yuan/share, the lowest purchase price is 69.70 yuan/share, and the total amount paid is 92.0759 million yuan (excluding stamp duty, trading commission, and other transaction fees).